• Je něco špatně v tomto záznamu ?

Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients

V. De Stefano, AM. Vannucchi, M. Ruggeri, F. Cervantes, A. Alvarez-Larrán, A. Iurlo, ML. Randi, L. Pieri, E. Rossi, P. Guglielmelli, S. Betti, E. Elli, MC. Finazzi, G. Finazzi, E. Zetterberg, N. Vianelli, G. Gaidano, I. Nichele, D. Cattaneo, M....

. 2016 ; 6 (11) : e493. [pub] 20161104

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc18016931

We retrospectively studied 181 patients with polycythaemia vera (n=67), essential thrombocythaemia (n=67) or primary myelofibrosis (n=47), who presented a first episode of splanchnic vein thrombosis (SVT). Budd-Chiari syndrome (BCS) and portal vein thrombosis were diagnosed in 31 (17.1%) and 109 (60.3%) patients, respectively; isolated thrombosis of the mesenteric or splenic veins was detected in 18 and 23 cases, respectively. After this index event, the patients were followed for 735 patient years (pt-years) and experienced 31 recurrences corresponding to an incidence rate of 4.2 per 100 pt-years. Factors associated with a significantly higher risk of recurrence were BCS (hazard ratio (HR): 3.03), history of previous thrombosis (HR: 3.62), splenomegaly (HR: 2.66) and leukocytosis (HR: 2.8). Vitamin K-antagonists (VKA) were prescribed in 85% of patients and the recurrence rate was 3.9 per 100 pt-years, whereas in the small fraction (15%) not receiving VKA more recurrences (7.2 per 100 pt-years) were reported. Intracranial and extracranial major bleeding was recorded mainly in patients on VKA and the corresponding rate was 2.0 per 100 pt-years. In conclusion, despite anticoagulation treatment, the recurrence rate after SVT in myeloproliferative neoplasms is high and suggests the exploration of new avenues of secondary prophylaxis with new antithrombotic drugs and JAK-2 inhibitors.

A O Ospedale Niguarda Ca' Granda Milano Italy

A O Santa Croce e Carle Cuneo Italy

A O Universitaria Messina Italy

A O Universitaria Policlinico di Bari Italy

Arcispedale Santa Maria Nuova IRCCS Reggio Emilia Italy

Center for Research and Innovation of Myeloproliferative Neoplasms A O U Careggi University of Florence Florence Italy

Clinica Medica 1 Università di Padova Padova Italy

Department of Hematology Hospital del Mar IMIM Barcelona Spain

Department of Hematology Institute Meir Medical Center Kfar Saba Israel

Department of Translational Medicine Università del Piemonte Orientale Vercelli Italy

Divisione di Ematologia Ospedale San Gerardo ASST Monza Italy

FROM Research Foundation ASST Papa Giovanni XXIII Bergamo Italy

Haemostasis Unit Department of Medical Surgical and Advanced Technologies Sciences 'G F Ingrassia' University of Catania Catania Italy

Hematology Division ASST Papa Giovanni XXIII Bergamo Italy

Hospital Clínic IDIBAPS Barcelona Spain

Hospital Clinico Valencia Spain

Institute of Hematology and Medical Oncology S Orsola Malpighi Hospital University of Bologna Bologna Italy

Institute of Hematology Catholic University Roma Italy

IRCCS Ospedale San Raffaele Milano Italy

Johannes Wesling Medical Center Minden University of Bochum Minden Germany

Oncohematology Division Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano Italy

Ospedale San Bortolo Vicenza Italy

Skane University Hospital Lund Sweden

University Hospital of Olomouc Olomouc Czech Republic

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18016931
003      
CZ-PrNML
005      
20180523130930.0
007      
ta
008      
180515s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/bcj.2016.103 $2 doi
035    __
$a (PubMed)27813534
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a De Stefano, V $u Institute of Hematology, Catholic University, Roma, Italy.
245    10
$a Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients / $c V. De Stefano, AM. Vannucchi, M. Ruggeri, F. Cervantes, A. Alvarez-Larrán, A. Iurlo, ML. Randi, L. Pieri, E. Rossi, P. Guglielmelli, S. Betti, E. Elli, MC. Finazzi, G. Finazzi, E. Zetterberg, N. Vianelli, G. Gaidano, I. Nichele, D. Cattaneo, M. Palova, MH. Ellis, E. Cacciola, A. Tieghi, JC. Hernandez-Boluda, E. Pungolino, G. Specchia, D. Rapezzi, A. Forcina, C. Musolino, A. Carobbio, M. Griesshammer, T. Barbui,
520    9_
$a We retrospectively studied 181 patients with polycythaemia vera (n=67), essential thrombocythaemia (n=67) or primary myelofibrosis (n=47), who presented a first episode of splanchnic vein thrombosis (SVT). Budd-Chiari syndrome (BCS) and portal vein thrombosis were diagnosed in 31 (17.1%) and 109 (60.3%) patients, respectively; isolated thrombosis of the mesenteric or splenic veins was detected in 18 and 23 cases, respectively. After this index event, the patients were followed for 735 patient years (pt-years) and experienced 31 recurrences corresponding to an incidence rate of 4.2 per 100 pt-years. Factors associated with a significantly higher risk of recurrence were BCS (hazard ratio (HR): 3.03), history of previous thrombosis (HR: 3.62), splenomegaly (HR: 2.66) and leukocytosis (HR: 2.8). Vitamin K-antagonists (VKA) were prescribed in 85% of patients and the recurrence rate was 3.9 per 100 pt-years, whereas in the small fraction (15%) not receiving VKA more recurrences (7.2 per 100 pt-years) were reported. Intracranial and extracranial major bleeding was recorded mainly in patients on VKA and the corresponding rate was 2.0 per 100 pt-years. In conclusion, despite anticoagulation treatment, the recurrence rate after SVT in myeloproliferative neoplasms is high and suggests the exploration of new avenues of secondary prophylaxis with new antithrombotic drugs and JAK-2 inhibitors.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a Buddův-Chiariho syndrom $x etiologie $x patofyziologie $7 D006502
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a polycythaemia vera $x komplikace $x patofyziologie $7 D011087
650    _2
$a vena portae $x patofyziologie $7 D011169
650    _2
$a primární myelofibróza $x komplikace $x patofyziologie $7 D055728
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a recidiva $7 D012008
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a rizikové faktory $7 D012307
650    _2
$a esenciální trombocytemie $x komplikace $x patofyziologie $7 D013920
650    _2
$a žilní trombóza $x etiologie $x patofyziologie $7 D020246
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Vannucchi, A M $u Center for Research and Innovation of Myeloproliferative Neoplasms, A.O.U. Careggi, University of Florence, Florence, Italy.
700    1_
$a Ruggeri, M $u Ospedale San Bortolo, Vicenza, Italy.
700    1_
$a Cervantes, F $u Hospital Clínic IDIBAPS, Barcelona, Spain.
700    1_
$a Alvarez-Larrán, A $u Department of Hematology, Hospital del Mar-IMIM, Barcelona, Spain.
700    1_
$a Iurlo, A $u Oncohematology Division, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy.
700    1_
$a Randi, M L $u Clinica Medica 1, Università di Padova, Padova, Italy.
700    1_
$a Pieri, L $u Center for Research and Innovation of Myeloproliferative Neoplasms, A.O.U. Careggi, University of Florence, Florence, Italy.
700    1_
$a Rossi, E $u Institute of Hematology, Catholic University, Roma, Italy.
700    1_
$a Guglielmelli, P $u Center for Research and Innovation of Myeloproliferative Neoplasms, A.O.U. Careggi, University of Florence, Florence, Italy.
700    1_
$a Betti, S $u Institute of Hematology, Catholic University, Roma, Italy.
700    1_
$a Elli, E $u Divisione di Ematologia, Ospedale San Gerardo, ASST Monza, Italy.
700    1_
$a Finazzi, M C $u Hematology Division, ASST Papa Giovanni XXIII, Bergamo, Italy.
700    1_
$a Finazzi, G $u Hematology Division, ASST Papa Giovanni XXIII, Bergamo, Italy.
700    1_
$a Zetterberg, E $u Skane University Hospital, Lund, Sweden.
700    1_
$a Vianelli, N $u Institute of Hematology and Medical Oncology, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
700    1_
$a Gaidano, G $u Department of Translational Medicine, Università del Piemonte Orientale, Vercelli, Italy.
700    1_
$a Nichele, I $u Ospedale San Bortolo, Vicenza, Italy.
700    1_
$a Cattaneo, D $u Oncohematology Division, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy.
700    1_
$a Palova, M $u University Hospital of Olomouc, Olomouc, Czech Republic.
700    1_
$a Ellis, M H $u Department of Hematology, Institute Meir Medical Center, Kfar Saba, Israel.
700    1_
$a Cacciola, E $u Haemostasis Unit, Department of Medical, Surgical and Advanced Technologies Sciences 'G.F. Ingrassia', University of Catania, Catania, Italy.
700    1_
$a Tieghi, A $u Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy.
700    1_
$a Hernandez-Boluda, J C $u Hospital Clinico, Valencia, Spain.
700    1_
$a Pungolino, E $u A.O. Ospedale Niguarda Ca' Granda, Milano, Italy.
700    1_
$a Specchia, G $u A.O. Universitaria, Policlinico di Bari, Italy.
700    1_
$a Rapezzi, D $u A.O. Santa Croce e Carle, Cuneo, Italy.
700    1_
$a Forcina, A $u IRCCS Ospedale San Raffaele, Milano, Italy.
700    1_
$a Musolino, C $u A.O. Universitaria, Messina, Italy.
700    1_
$a Carobbio, A $u FROM Research Foundation, ASST Papa Giovanni XXIII, Bergamo, Italy.
700    1_
$a Griesshammer, M $u Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany.
700    1_
$a Barbui, T $u FROM Research Foundation, ASST Papa Giovanni XXIII, Bergamo, Italy.
773    0_
$w MED00187996 $t Blood cancer journal $x 2044-5385 $g Roč. 6, č. 11 (2016), s. e493
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27813534 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180523131115 $b ABA008
999    __
$a ok $b bmc $g 1300555 $s 1013771
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 6 $c 11 $d e493 $e 20161104 $i 2044-5385 $m Blood cancer journal $n Blood Cancer J $x MED00187996
LZP    __
$a Pubmed-20180515

Najít záznam

Citační ukazatele

Možnosti archivace